Derma Sciences, Inc. Announces Licensing Agreement with C-Boot Ltd to Market MOBILITY-1 for Treatment of Vascular Diseases

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (OTCBB: DSCI), a manufacturer and full line supplier of wound and skin care products, today announced that it has obtained a licensing agreement with C-Boot LTD, a medical biosystems company based in Israel, for the marketing, sales and distribution rights of C-Boot’s patented advanced therapeutic devices for the treatment of Chronic Venous Insufficiency (CVI), Deep Vein Thrombosis (DVT) prevention, venous ulcers, lymphedema, and other conditions that require compression therapy, including the enhancement of blood circulation during recovery from coronary artery bypass graft surgery and orthopedic hip and knee replacements. C-Boot’s products, which will be marketed by Derma Sciences under the MOBILITY-1TM brand, include a lightweight wearable dynamic compression device that periodically inflates and deflates thereby producing segmented and therapeutically significant compression. The technologies inherent within the device are covered by several US patents.